pHR_PGK_LaG16_2_synNotch_Gal4VP64 Citations (4)

Originally described in: Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors.
Roybal KT, Williams JZ, Morsut L, Rupp LJ, Kolinko I, Choe JH, Walker WJ, McNally KA, Lim WA Cell. 2016 Oct 6;167(2):419-432.e16. doi: 10.1016/j.cell.2016.09.011. Epub 2016 Sep 29. PubMed Journal

---

Articles Citing pHR_PGK_LaG16_2_synNotch_Gal4VP64

Articles
A Promising Intracellular Protein-Degradation Strategy: TRIMbody-Away Technique Based on Nanobody Fragment. Chen G, Kong Y, Li Y, Huang A, Wang C, Zhou S, Yang Z, Wu Y, Ren J, Ying T. Biomolecules. 2021 Oct 14;11(10). pii: biom11101512. doi: 10.3390/biom11101512. PubMed
Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Goyette MA, Stevens LE, DePinho CR, Seehawer M, Nishida J, Li Z, Wilde CM, Li R, Qiu X, Pyke AL, Zhao S, Lim K, Tender GS, Northey JJ, Riley NM, Long HW, Bertozzi CR, Weaver VM, Polyak K. Proc Natl Acad Sci U S A. 2024 May 14;121(20):e2322688121. doi: 10.1073/pnas.2322688121. Epub 2024 May 6. PubMed
Preclinical efficacy of a HER2 synNotch/CEA-CAR combinatorial immunotherapy against colorectal cancer with HER2 amplification. Cortese M, Torchiaro E, D'Andrea A, Petti C, Invrea F, Franco L, Donini C, Leuci V, Leto SM, Vurchio V, Cottino F, Isella C, Arena S, Vigna E, Bertotti A, Trusolino L, Sangiolo D, Medico E. Mol Ther. 2024 Aug 7;32(8):2741-2761. doi: 10.1016/j.ymthe.2024.06.023. Epub 2024 Jun 17. PubMed
Microenvironment actuated CAR T cells improve solid tumor efficacy without toxicity. Vogt KC, Silberman PC, Lin Q, Han JE, Laflin A, Gellineau HA, Heller DA, Scheinberg DA. Sci Adv. 2025 Jan 24;11(4):eads3403. doi: 10.1126/sciadv.ads3403. Epub 2025 Jan 22. PubMed

If you have published an article using this material, please email us at to have your article added to this page.